Humus Capital Partners LLC is a private equity firm based in Buenos Aires, Argentina, founded in 2010. The firm focuses on middle market and emerging growth investments, with a particular interest in industry consolidation, buyouts, turnarounds, and growth capital. Humus Capital avoids investments in the land and agriculture sectors, instead concentrating on companies in animal protein, frozen foods, hospitality and leisure, education, healthcare, and retail, particularly within the agribusiness sector in Latin America. The firm typically invests around $20 million in its portfolio companies and prefers to acquire a majority stake. Additionally, Humus Capital aims to take an active role in its investments by securing a seat on the board of directors and plans to exit through initial public offerings or sales to strategic buyers.
Biosidus S.A., a biotechnology company, develops, manufactures, and supplies biosimilars. The company’s product portfolio includes eight therapeutic proteins and retuximab and etanercept product candidates. It offers Epoetin, a synthetic human erythropoietin; Filgrastim, a recombinant methionyl human granulocyte colony stimulating factor; Somatropin, Sinthetic version of human growth hormone; and Lenograstim, Granulocyte colony stimulating factor. Additionally, the company focuses on transgenic animals and gene therapy applied to the management of central and peripheral vascular disease. Biosidus S.A. was founded in 1983 and is based in Buenos Aires, Argentina.